Seoul-based IVI Partners With Indian Shantha Biotechnics For Low-Cost Cholera Vaccine Licensed in India
This article was originally published in PharmAsia News
Executive SummarySEOUL - A new oral cholera vaccine developed by Seoul-based International Vaccine Institute has been licensed to India's Shantha Biotechnics, paving the way for worldwide use of a low-cost cholera vaccine in developing countries, where most cholera cases occur, the IVI said
You may also be interested in...
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.